12:00 AM
 | 
Mar 19, 2012
 |  BC Week In Review  |  Company News  |  Deals

ThromboGenics, Novartis deal

ThromboGenics granted Novartis' Alcon Inc. ophthalmic unit ex-U.S. rights to commercialize symptomatic vitreomacular adhesion (VMA) candidate ocriplasmin. The product is under review in Europe for the indication. ThromboGenics will receive an upfront payment of €75 million ($98.4 million) and is eligible for €90 million ($118 million) in near-term milestones, plus...

Read the full 227 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >